# A Phase 2 Study of HB0017 in Psoriasis Patients

> **NCT06592274** · PHASE2 · RECRUITING · sponsor: **Huabo Biopharm Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Psoriasis (PsO)

## Interventions

- **BIOLOGICAL:** HB0017
- **BIOLOGICAL:** HB0017
- **BIOLOGICAL:** HB0017

## Key facts

- **NCT ID:** NCT06592274
- **Lead sponsor:** Huabo Biopharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06592274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06592274, "A Phase 2 Study of HB0017 in Psoriasis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06592274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*